Impact of insulin delivery devices in diabetes care

Diabetes Technology and Therapeutics

Volumn 12, Issue SUPPL. 1, 2010, Pages

  Garg, Satish K ^a,b  

^a UNIVERSITY OF COLORADO DENVER   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; INSULIN; INSULIN ASPART; INSULIN GLULISINE; INSULIN LISPRO;

BLOOD GLUCOSE MONITORING; CONTINUOUS INFUSION; DIABETIC KETOACIDOSIS; DISPOSABLE EQUIPMENT; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; EDITORIAL; GLYCEMIC CONTROL; HEALTH CARE COST; HEALTH INSURANCE; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN INFUSION; INSULIN PUMP; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT CARE; PATIENT EDUCATION; PRIORITY JOURNAL; RISK FACTOR;

DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; EQUIPMENT DESIGN; HUMANS; HYPOGLYCEMIC AGENTS; INJECTIONS, SUBCUTANEOUS; INSULIN; INSULIN INFUSION SYSTEMS;

EID: 77956168089     PISSN: 15209156     EISSN: None     Source Type: Journal    
DOI: 10.1089/dia.2010.0045     Document Type: Editorial

References (31)

1. Garg SK: The future of continuous glucose monitoring. Diabetes Technol Ther 2009;11(Suppl 1):S1-S3.
2. The effect of intensive treatment of diabetes on the development and progression of long-term complication in insulin dependent diabetes mellitus. The Diabetes Control and Complication Trial Research Group. N Engl J Med 1993;329: 977-986.
3. Writing Team for the Diabetes Control and Complication Trial/Epidemiology of Diabetes Interventions and Complications Research Study: sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetes nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study. JAMA 2003;290:2159-2167.
4. Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, Raskin P, Zinman B; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group: Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005; 353:2643-2653.
5. Valentine V, Kruger DF: Considerations in insulin delivery device selection. Diabetes Technol Ther 2010;12(Suppl 1): S98-S100.
6. Asche CV, Shane-McWhorter L, Reparla S: Health economics and compliance of vials/syringes versus pen devices: a review of the evidence. Diabetes Technol Ther 2010;12(Suppl 1):S101-S108.
7. Bode BW: Insulin pump use in type 2 diabetes. Diabetes Technol Ther 2010;12(Suppl 1):S-17-S-21.
8. Luijf YM, DeVries JH: Dosing accuracy of insulin pens versus conventional syringes and vials. Diabetes Technol Ther 2010;12(Suppl 1):S-73-S-77.
9. Perfetti R: Reusable and disposable insulin pens for the treatment of diabetes: understanding the global differences in user preference and an evaluation of inpatient insulin pen use. Diabetes Technol Ther 2010;12(Suppl 1):S-79-S-85.
10. Bailey TS, Edelman SV: Insulin pen use for type 2 diabetes-a clinical perspective. Diabetes Technol Ther 2010;12(Suppl 1):S86-S90.
11. Shetty G, Wolpert H: Insulin pump use in adults with type 1 diabetes-practical issues. Diabetes Technol Ther 2010; 12(Suppl 1):S-11-S-16.
12. Hirsch IB: Practical pearls in insulin pump therapy. Diabetes Technol Ther 2010;12(Suppl 1):S23-S27.
13. Bell DSH, Ovalle F: Improved glycemic control with use of continuous subcutaneous insulin infusion compared with multiple insulin injection therapy. Endocr Pract 2000;6:357-360.
14. Chantelau E, Spraul M, Muhlhauser I, Gause R, Berger M: Long-term safety, efficacy and side-effects of continuous subcutaneous insulin infusion treatment for type 1 (insulin-dependent) diabetes mellitus: a one centre experience. Dia-betologia 1989;32:421-426.
15. Pickup JC, Kidd J, Burmiston S, Yemane N: Determinants of glycaemic control in type 1 diabetes during intensified therapy with multiple daily insulin injections or continuous subcutaneous insulin infusion: importance of blood glucose variability. Diabetes Metab Res Rev 2006;22:232-237.
16. Rudolph JW, Hirsch IB: Assessment of therapy with continuous subcutaneous insulin infusion in an academic diabetes clinic. Endocr Pract 2002;8:401-405.
17. Boland EA, Grey M, Oesterle A, Fredrickson L, Tamborlane WV: Continuous subcutaneous insulin infusion. A new way to lower risk of severe hypoglycemia improve metabolic control, and enhance coping in adolescents with type 1 diabetes. Diabetes Care 1999;22:1779-1784.
18. Maniatis AK, Klingensmith GJ, Slover RH, Mowry CJ, Chase HP: Continuous subcutaneous insulin infusion therapy for children and adolescents: an option for routine diabetes care. Pediatrics 2001;107:351-356.
19. Litton J, Rice A, Friedman N, Oden J, Lee MM, Freemark M: Insulin pump therapy in toddlers and preschool children with type 1 diabetes mellitus. J Pediatr 2002;141:490-495.
20. Bruttomesso D, Pianta A, Crazzolara D, Scaldaferri E, Lora L, Guarneri G, Mongillo A, Gennaro R, Miola M, Moretti M, Confortin L, Beltramello GP, Pais M, Baritussio A, Casiglia E, Tiengo A: Continuous subcutaneous insulin infusion (CSII) in the Veneto region: efficacy, acceptability and quality of life. Diabet Med 2002;19:628-634.
21. Wollitzer A, Zisser H, Jovanovic L: Insulin pumps and their use in pregnancy. Diabetes Technol Ther 2010;12(Suppl 1): S33-S36.
22. Maahs DM, Horton LA, Chase HP: The use of insulin pumps in youth with type 1 diabetes. Diabetes Technol Ther 2010;12(Suppl 1):S-59-S-65.
23. Renard E: Insulin pump use in Europe. Diabetes Technol Ther 2010;12(Suppl 1):S-29-S-32.
24. Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group, Bode B, Beck RW, Xing D, Gilliam L, Hirsch I, Kollman C, Laffel L, Ruedy KJ, Tamborlane WV, Weinzimer S, Wolpert H: Sustained benefit of continuous glucose monitoring on A1c, glucose profiles and hypogly-cemia in adults with type 1 diabetes. Diabetes Care 2009;32:2047-2049.
25. Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group: The effect of continuous glucose monitoring in well-controlled type 1 diabetes. Diabetes Care 2009;32:1378-1383.
26. Garg S, Jovanovic L: Relationship of fasting and hourly blood glucose levels to hbA1c values: safety, accuracy, and improvements in glucose profiles obtained using a 7-day continuous glucose sensor. Diabetes Care 2006;29:2644-2649.
27. Garg S, Zisser H, Schwartz S, Bailey T, Kaplan R, Ellis S, Jovanovic L: Improvement in glycemic excursions with a transcutaneous, real-time continuous glucose sensor: a randomized controlled trial. Diabetes Care 2006;29:44-50.
28. Ellis SL, Bookout T, Izuora KE, Garg SK: Use of continuous glucose monitoring to improve diabetes mellitus management. Endocrinol Metab Clin North Am 2007;36(Suppl 2):44-68.
29. Kerr D, Olateju T: Pascal's wager: combining continuous glucose monitoring and continuous subcutaneous insulin infusion. Diabetes Technol Ther 2010;12(Suppl 1):S43-S50.
30. Hovorka R, Allen JM, Elleri D, Chassin LJ, Harris J, Xing D, Kollman C, Hovorka T, Larsen AM, Nodale M, De Palma A, Wilinska ME, Acerini CL, Dunger DB: Manual closed-loop insulin delivery in children and adolescents with type 1 diabetes: a phase 2 randomised crossover trial. Lancet 2010; 375:743-751.
31. Anhalt H, Bohannon NJV: Insulin patch pumps: their development and future in closed-loop systems. Diabetes Technol Ther 2010;12(Suppl 1):S-51-S-58.